Cough News and Research RSS Feed - Cough News and Research

Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD. [More]
CDC publishes reports on infectious and noninfectious diseases

CDC publishes reports on infectious and noninfectious diseases

Beginning with the Oct. 23, 2015, Supplements to Morbidity and Mortality Weekly Report (MMWR), CDC will publish the summaries of all notifiable conditions – infectious and noninfectious – at the same time. [More]
Researchers to present case report of acute inhalation lung injury related to use of e-cigarettes

Researchers to present case report of acute inhalation lung injury related to use of e-cigarettes

Researchers from White River Junction VA Hospital, in Junction, Vermont, will present a case report of acute inhalation lung injury related to the use of e-cigarettes and a flavored e-cigarette liquid containing diacetyl. [More]
Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Takeda Pharmaceuticals, U.S.A., Inc., today announced that data highlighting the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), will be presented during the 2015 American College of Gastroenterology Annual Scientific Meeting in Honolulu, Hawaii, held on October 16-21. [More]
Synapse Biomedical, IFR to commercialize implantable systems that restore muscle function in paralyzed patients

Synapse Biomedical, IFR to commercialize implantable systems that restore muscle function in paralyzed patients

Case Western Reserve University's Institute for Functional Restoration (IFR) and Synapse Biomedical Inc. have entered a partnership to commercialize fully implantable systems that restore muscle function in paralyzed patients. [More]
Get your flu shot before fall festivities, says Loyola infectious disease specialist

Get your flu shot before fall festivities, says Loyola infectious disease specialist

While planning your family's fall festivities this month, add the flu shot to the list. Then follow through with a visit to your doctor to make sure everyone is protected for the flu season. October is the recommended month to receive the vaccine for your best shot at preventing the flu. [More]
FDA approves Opdivo to treat patients with advanced non-small cell lung cancer

FDA approves Opdivo to treat patients with advanced non-small cell lung cancer

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy. [More]
FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP). Promacta can be used in these children when they have not achieved an appropriate response using other ITP medicines or surgery to remove the spleen. [More]
FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors. [More]
Acetaminophen Awareness Coalition issues safety message to consumers about flu medicines

Acetaminophen Awareness Coalition issues safety message to consumers about flu medicines

With cold and flu season around the corner, consumers will soon begin to purchase medicines such as cough syrup, throat lozenges, and nasal sprays to help get relief from symptoms such as fever, coughs, congestion, and more. Many of the medicines used to treat these cold and flu symptoms can contain common drug ingredients such as acetaminophen. [More]
Tris Pharma announces launch of generic TUSSIONEX

Tris Pharma announces launch of generic TUSSIONEX

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced the launch of Tris-labeled generic TUSSIONEX, an extended-release suspension containing hydrocodone polistirex and chlorpheniramine polistirex. [More]
Primary care doctors ill-prepared to cope with rising demand for cancer care in high-income countries

Primary care doctors ill-prepared to cope with rising demand for cancer care in high-income countries

Leading primary care professionals and cancer experts will warn at the Royal College of General Practitioners annual congress in Glasgow, UK that primary care doctors will not be able to cope with the rising demand for cancer care in high-income countries – predicted to double within the next 15 years. [More]
GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib compared to erlotinib for the treatment of patients with previously treated advanced SCC of the lung [More]
New article provides advice on handling mid-air health crises

New article provides advice on handling mid-air health crises

A medical emergency that strikes in mid-air is a scary prospect for any traveler, but it presents a particularly complex situation for physicians and other healthcare providers. [More]
Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. [More]
Outbreak of Bordetella parapertussis occurred in Southeastern Minnesota in 2014: Study

Outbreak of Bordetella parapertussis occurred in Southeastern Minnesota in 2014: Study

Study reports that an outbreak of Bordetella parapertussis occurred in 2014 in Southeastern Minnesota, in the months of October through December. This research is presented at ASM's 55th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC/ICC). [More]
Hermansky-Pudlak syndrome can cause debilitating lung disease in Puerto Ricans

Hermansky-Pudlak syndrome can cause debilitating lung disease in Puerto Ricans

A hereditary condition called Hermansky-Pudlak syndrome (HPS) can cause bleeding problems, low vision, albinism and, in some patients, a debilitating lung disease. [More]
Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation. [More]
ACP awarded $1,002,884 Cooperative Agreement to increase adult immunization rates in US

ACP awarded $1,002,884 Cooperative Agreement to increase adult immunization rates in US

The American College of Physicians (ACP) was awarded a $1,002,884 Cooperative Agreement from the Centers for Disease Control and Prevention (CDC) to increase immunization rates in the United States. [More]

Bracket completes EXACT e-Diary Certification program on Android smartphone and tablet

Bracket, one of the industry's leading eCOA solutions providers today announced that it has completed the e-Diary Certification program with Evidera™ for the EXACT patient daily e-Diary on both an Android smartphone, and an Android Tablet. [More]
Advertisement
Advertisement